Tag: MannKind Corp

Finance

Biotech Bearish Stocks: MannKind Corporation (NASDAQ:MNKD), Exelixis (NASDAQ:EXEL), Inovio Pharmaceuticals (NYSEMKT:INO), EXACT Sciences (NASDAQ:EXAS)

An FDA report raised questions regarding Mannkind Corporation (NASDAQ:MNKD)’s diabetes device Afrezza ahead of an April 1 meeting of outside advisers to the FDA. The drug has yet to be approved by the FDA as there are concerns over certain pharmacology issues that could impact Afreeza’s safety and effectiveness. MannKind Corporation (NASDAQ:MNKD) stock performance was -7.12% in last session and finished the day at $4.83. … Continue reading Biotech Bearish Stocks: MannKind Corporation (NASDAQ:MNKD), Exelixis (NASDAQ:EXEL), Inovio Pharmaceuticals (NYSEMKT:INO), EXACT Sciences (NASDAQ:EXAS)

Colin Pettis
Finance

Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE) announced that PROFILE 1014, a phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) when compared to standard platinum-based chemotherapy regimens. Pfizer Inc. (NYSE:PFE) stock performance was 1.13% in last session and finished the day at $32.18. … Continue reading Healthcare Most Active: Pfizer Inc. (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis
Finance

Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. … Continue reading Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Colin Pettis
Finance

Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was -7.98% in last session and finished the day at $3.23. … Continue reading Biotech Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA)

Jayne Crisman
Finance

Worth watching Stocks: Arch Coal (NYSE:ACI), MannKind Corporation (NASDAQ:MNKD), AK Steel Holding (NYSE:AKS), Arena Pharmaceuticals (NASDAQ:ARNA)

Arch Coal Inc (NYSE:ACI) has been given a consensus rating of “Hold” by the eighteen brokerages that are presently covering the company, AnalystRatingsNetwork.com reports. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating on the company. Arch Coal Inc (NYSE:ACI) stock performance was -0.64% in last session and finished the … Continue reading Worth watching Stocks: Arch Coal (NYSE:ACI), MannKind Corporation (NASDAQ:MNKD), AK Steel Holding (NYSE:AKS), Arena Pharmaceuticals (NASDAQ:ARNA)

Kristen Barton
Finance

Biotech Active Stocks: Arrowhead Research (NASDAQ:ARWR), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX), MannKind Corporation (NASDAQ:MNKD)

Arrowhead Research Corp (NASDAQ:ARWR) stock had its “buy” rating reaffirmed by stock analysts at Deutsche Bank in a report issued on Monday, American Banking News.com reports. Arrowhead Research Corp (NASDAQ:ARWR) stock performance was -16.09% in last session and finished the day at $17.37. Traded volume was 7.56million shares in the last session and the average volume of the stock remained 1.44million shares. The beta of … Continue reading Biotech Active Stocks: Arrowhead Research (NASDAQ:ARWR), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX), MannKind Corporation (NASDAQ:MNKD)

Chris Lewis